Advertisement
U.S. markets close in 2 hours 19 minutes
  • S&P 500

    5,084.64
    +14.88 (+0.29%)
     
  • Dow 30

    38,925.78
    -23.24 (-0.06%)
     
  • Nasdaq

    16,034.42
    +86.68 (+0.54%)
     
  • Russell 2000

    2,052.28
    +11.98 (+0.59%)
     
  • Crude Oil

    78.52
    -0.02 (-0.03%)
     
  • Gold

    2,053.80
    +11.10 (+0.54%)
     
  • Silver

    22.88
    +0.24 (+1.08%)
     
  • EUR/USD

    1.0808
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.2480
    -0.0260 (-0.61%)
     
  • GBP/USD

    1.2622
    -0.0038 (-0.30%)
     
  • USD/JPY

    149.9050
    -0.7280 (-0.48%)
     
  • Bitcoin USD

    60,742.30
    +423.57 (+0.70%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,630.02
    +5.04 (+0.07%)
     
  • Nikkei 225

    39,166.19
    -41.84 (-0.11%)
     

Here's What Key Metrics Tell Us About TransMedics (TMDX) Q3 Earnings

TransMedics (TMDX) reported $66.43 million in revenue for the quarter ended September 2023, representing a year-over-year increase of 158.7%. EPS of -$0.12 for the same period compares to -$0.25 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $48.05 million, representing a surprise of +38.25%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.18.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how TransMedics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Geographic Revenues- United States: $59.69 million compared to the $44.90 million average estimate based on three analysts. The reported number represents a change of +156.4% year over year.

  • Geographic Revenues- All other countries: $4.30 million compared to the $3.44 million average estimate based on three analysts. The reported number represents a change of +79.3% year over year.

  • Net revenue by OCS product- OCS Lung net revenue: $3.72 million versus the three-analyst average estimate of $2.80 million. The reported number represents a year-over-year change of +132.7%.

  • Net revenue by OCS product- OCS Liver net revenue: $41.31 million versus the three-analyst average estimate of $29.65 million. The reported number represents a year-over-year change of +229.4%.

  • Net revenue by OCS product- OCS Heart net revenue: $18.96 million compared to the $15.88 million average estimate based on three analysts. The reported number represents a change of +64.3% year over year.

View all Key Company Metrics for TransMedics here>>>

Shares of TransMedics have returned +32% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

TransMedics Group, Inc. (TMDX) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Advertisement